FORMULATION AND EVALUATION OF MUCOADHESIVE BUCCAL TABLETS OF CANDESARTAN

Abstract

Candesartan is  an  angiotensin  II  receptor antagonist  and  is  widely  used  in  the  management  of  hypertension  to  reduce  cardiovascular mortality  in patients with left  ventricular  dysfunction  following  myocardial  infarction,  and  in  the  management  of  heart  failure. The Mucoadhesive buccal tablets were prepared by direct compression method using carbopol 934, HPMC K4M, sodium CMC as mucoadhesive polymer. The compatibility studies of drug and excipients were performed by FT-IR spectroscopy. After examining the flow properties of the powder blends the results are found to be within prescribed limits and indicated good flowing property, hence it was subjected to tablet compression. The tablets were evaluated for post-compression parameters like weight variation, hardness, thickness, friability, drug content uniformity, Surface pH, in-vitro studies like swelling, mucoadhesive strength and drug release. Formulation (F6) containing Carbopol-934 and Sodium CMC in the ratio of (2: 3) showed good mucoadhesive strength (36.14) and maximum drug release of 98.15% in 8 hrs. Swelling increases with increase in concentration of Sodium CMC in tablets. The drug content of shown highest of 99.15 %, Surface pH was found to be 6.42. All the evaluation parameters given the positive results and comply with the standards. Stability studies were carried out on the developed formulations indicated that the formulations were stable during the study period. The results indicate that the mucoadhesive buccal tablets of Candesartan may be good choice to bypass the extensive hepatic first pass metabolism with an improvement in the bioavailability of candesartan through buccal mucosa.

Key Words: Mucoadhesive buccal tablets, direct compression, Hypertension, Candesartan cilexetil,